Skip to content
Markets News
Stocks1 min read

Rezolute Reports Positive Preliminary Phase 3 Results for Tumor HI

Makkler Newsroom
November 13, 2026 · Based on reporting by GlobeNewswire

Thirteen participants met the study’s response criterion, while three remain in the pivotal phase ahead of final results expected in December.

Key takeaways

  • Thirteen participants met the response criterion in Rezolute’s upLIFT study.
  • Final topline results and statistical analysis are expected by mid-December 2026.

Rezolute said preliminary results from its Phase 3 upLIFT study in tumor hyperinsulinism showed that the primary efficacy endpoint had been achieved. The November 5 evaluation found 13 participants met the response criterion.

The endpoint measures whether patients achieve at least a 50% reduction in glucose infusion rate. Of the 13 responders, 12 also stopped intravenous glucose completely. Three participants remain in the pivotal phase, including two who have not yet met the response criterion.

Rezolute expects to report topline results and statistical analysis by mid-December 2026. Ersodetug remains investigational, and the company’s announcement did not report final study results.

Topics
Further reading

This article was produced with the help of AI technology. Based on reporting by the outlets listed above.

Comments (0)

Log in to join the discussion.Log in

No comments yet - be the first to weigh in.